Key result
Newer antihypertensive agents require substantial cardiovascular risk reduction to demonstrate cost-effectiveness over traditional therapy.
Why the study?
Decision makers need to evaluate the characteristics required for newer antihypertensive therapies to be more cost-effective than traditional drug treatment for hypertension.
Cost-effectiveness analysis, a set of methods for estimating the costs and health effects of medical interventions, helps decision makers to compare alternative treatments and to decide which interventions are appropriate in which situations. This article outlines some fundamental principles of cost-effectiveness analysis and discusses the characteristics necessary if alternative therapies are to be more cost-effective than traditional drug treatment for hypertension. The discussion focuses primarily on the newer drugs like angiotensin converting enzyme inhibitors, alpha-adrenergic receptor blockers, and calcium antagonists.
No takes yet. Share an insight, caveat, or question.
Louise B. Russell (1989) conducted a review in Hypertension. Newer antihypertensive drugs (ACE inhibitors, alpha-adrenergic receptor blockers, calcium antagonists) vs. Traditional drug treatment for hypertension was evaluated on Cost-effectiveness. Newer antihypertensive drugs like ACE inhibitors, alpha-blockers, and calcium antagonists are discussed regarding the principles needed to be more cost-effective than traditional therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: